The average patient with Type 1 diabetes is paying twice as much for insulin, before subtracting rebates and discounts, as they were just a few years ago, according to a report from the Health Care Cost Institute.
By the numbers: The average patient with Type 1 diabetes spent $5,705 insulin in 2016, according to HCCI.
There is a major caveat.
The bottom line: Nothing here is about to change. Two of the three major insulin makers, Sanofi and Novo Nordisk, have raised prices on their products for this year. (The third, Eli Lilly, has yet to make a public announcement.)
What theyâ€™re saying: Sanofi and Novo Nordisk both issued statements that blamed rebates, high deductibles and other insurance designs as the reasons for higher spending, and they said most of their patients can get insulin for less than $50 per month.